[HTML][HTML] Alzheimer's disease: an updated overview of its genetics

J Andrade-Guerrero, A Santiago-Balmaseda… - International journal of …, 2023 - mdpi.com
Alzheimer's disease (AD) is the most common neurodegenerative disease in the world. It is
classified as familial and sporadic. The dominant familial or autosomal presentation …

[HTML][HTML] Metalloproteinases and their inhibitors: potential for the development of new therapeutics

M Raeeszadeh-Sarmazdeh, LD Do, BG Hritz - Cells, 2020 - mdpi.com
The metalloproteinase (MP) family of zinc-dependent proteases, including matrix
metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs), and a disintegrin …

Physiology and pharmacology of amyloid precursor protein

Y Cho, HG Bae, E Okun, TV Arumugam… - Pharmacology & …, 2022 - Elsevier
Amyloid precursor protein (APP) is an evolutionarily conserved transmembrane protein and
a well-characterized precursor protein of amyloid-beta (Aβ) peptides, which accumulate in …

[HTML][HTML] A review on natural antioxidants for their role in the treatment of Parkinson's disease

P Mittal, S Dhankhar, S Chauhan, N Garg… - Pharmaceuticals, 2023 - mdpi.com
The neurodegenerative condition known as Parkinson's disease (PD) is brought on by the
depletion of dopaminergic neurons in the basal ganglia, which is the brain region that …

[HTML][HTML] The emerging role of furin in neurodegenerative and neuropsychiatric diseases

Y Zhang, X Gao, X Bai, S Yao, YZ Chang… - Translational …, 2022 - Springer
Furin is an important mammalian proprotein convertase that catalyzes the proteolytic
maturation of a variety of prohormones and proproteins in the secretory pathway. In the …

[HTML][HTML] Targeting ADAM10 in cancer and autoimmunity

TM Smith Jr, A Tharakan, RK Martin - Frontiers in immunology, 2020 - frontiersin.org
Generating inhibitors for AD isintegrin A nd M etalloproteinase 10 (ADAM10), a zinc-
dependent protease, was heavily invested in by the pharmaceutical industry starting over 20 …

Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands

A Iraji, M Khoshneviszadeh, O Firuzi… - Bioorganic …, 2020 - Elsevier
Alzheimer's Disease (AD) is a progressive neurodegenerative disorder that effects 50 million
people worldwide. In this review, AD pathology and the development of novel therapeutic …

Synaptic dysfunction in early phases of Alzheimer's Disease

S Pelucchi, F Gardoni, M Di Luca, E Marcello - Handbook of clinical …, 2022 - Elsevier
The synapse is the locus of plasticity where short-term alterations in synaptic strength are
converted to long-lasting memories. In addition to the presynaptic terminal and the …

[HTML][HTML] Redox-active metal ions and amyloid-degrading enzymes in Alzheimer's disease

N Kim, HJ Lee - International Journal of Molecular Sciences, 2021 - mdpi.com
Redox-active metal ions, Cu (I/II) and Fe (II/III), are essential biological molecules for the
normal functioning of the brain, including oxidative metabolism, synaptic plasticity …

miR-30a-5p induces Aβ production via inhibiting the nonamyloidogenic pathway in Alzheimer's disease

T Sun, K Zhao, M Liu, Z Cai, L Zeng, J Zhang… - Pharmacological …, 2022 - Elsevier
Alzheimer's disease (AD) pathogenesis is known to involve a dysregulation of microRNA
expression, and these intricate transcriptional cascades between multiple pathological …